Lava Therapeutics Nv (LVTX)

Feb 28, 2025

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang - Benzinga

Feb 28, 2025

Feb 27, 2025

This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga

Feb 27, 2025

Feb 25, 2025

LAVA Therapeutics Reviews Strategic Alternatives, Announces 30% Staff Cut - Nasdaq

Feb 25, 2025

Feb 25, 2025

LAVA Therapeutics Announces Restructuring Plan for 2025 - TipRanks

Feb 25, 2025

Feb 25, 2025

LAVA Announces Evaluation of Strategic Options - GlobeNewswire

Feb 25, 2025

Feb 25, 2025

Can LAVA Therapeutics Find a Buyer? Company Cuts 30% of Staff While Exploring Strategic Options - StockTitan

Feb 25, 2025

Feb 12, 2025

LVTX stock touches 52-week low at $0.88 amid market challenges - Investing.com Canada

Feb 12, 2025

Feb 12, 2025

LVTX stock touches 52-week low at $0.88 amid market challenges By Investing.com - Investing.com South Africa

Feb 12, 2025

Feb 06, 2025

LAVA Therapeutics (NASDAQ:LVTX) Stock Price Down 4.6% – Here’s What Happened - Defense World

Feb 06, 2025

Jan 27, 2025

RNA Editing Market Top Companies StudyQIAGEN N.V., UniquQuire - openPR

Jan 27, 2025

Jan 10, 2025

LAVA Therapeutics begins trial for cancer treatment - Investing.com India

Jan 10, 2025

Jan 10, 2025

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - GlobeNewswire

Jan 10, 2025

Jan 10, 2025

LAVA Therapeutics Initiates Phase 1 Trial for Novel Leukemia Treatment LAVA-1266 - StockTitan

Jan 10, 2025

Jan 09, 2025

LAVA Therapeutics NV (LVTX)’S -5.56% Retreat Makes It Worth Considering Again - Stocks Register

Jan 09, 2025

Jan 04, 2025

LAVA Therapeutics NV Files 8-K with SEC, Transitioning to U.S. Domestic Issuer Status - Defense World

Jan 04, 2025

Dec 26, 2024

LVTX stock touches 52-week low at $0.95 amid market challenges - Investing.com

Dec 26, 2024

Dec 20, 2024

H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization By Investing.com - Investing.com South Africa

Dec 20, 2024

Dec 20, 2024

H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization - Investing.com

Dec 20, 2024

Dec 18, 2024

LAVA Therapeutics stock hits 52-week low at $0.98 - Investing.com

Dec 18, 2024

Dec 17, 2024

Lava Therapeutics' SWOT analysis: stock faces challenges after key asset discontinuation - Investing.com

Dec 17, 2024

Dec 16, 2024

Research Analysts Issue Forecasts for LVTX Q1 Earnings - Defense World

Dec 16, 2024

Dec 14, 2024

LAVA Therapeutics (NASDAQ:LVTX) Rating Lowered to “Hold” at Leerink Partnrs - Defense World

Dec 14, 2024

Dec 13, 2024

Leerink Partners Downgrades LAVA Therapeutics N.V. (LVTX) - MSN

Dec 13, 2024

Dec 12, 2024

Leerink cuts Lava Therapeutics stcok to Market Perform By Investing.com - Investing.com Nigeria

Dec 12, 2024

Dec 12, 2024

Leerink cuts Lava Therapeutics stcok to Market Perform - Investing.com India

Dec 12, 2024

Dec 12, 2024

JMP Securities Downgrades LAVA Therapeutics N.V. (LVTX) - MSN

Dec 12, 2024

Dec 11, 2024

LAVA Therapeutics stock hits 52-week low at $1.35 - Investing.com

Dec 11, 2024

Dec 11, 2024

Lava Therapeutics' SWOT analysis: biotech stock shows promise amid challenges - Investing.com Nigeria

Dec 11, 2024

Dec 10, 2024

LAVA Reports Third Quarter 2024 Financial Results and - GlobeNewswire

Dec 10, 2024

Dec 10, 2024

LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Dec 10, 2024

Dec 10, 2024

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027 - The Manila Times

Dec 10, 2024

Dec 10, 2024

LAVA Therapeutics Pivots Strategy, Advances Cancer Drug Pipeline with Pfizer and J&J Partnerships - StockTitan

Dec 10, 2024

Dec 04, 2024

LAVA Therapeutics (NASDAQ:LVTX) Trading Down 5.6% – Time to Sell? - Defense World

Dec 04, 2024

Nov 12, 2024

Some Major Key Players In The RNA Editing Market: - InsightAce Analytic

Nov 12, 2024

Sep 30, 2024

Lava Therapeutics' SWOT analysis: oncology biotech's stock potential amid trials - Investing.com UK

Sep 30, 2024

Sep 25, 2024

ACAD: 3 Healthcare Stocks Analysts Expect to Rally Over 50% - StockNews.com

Sep 25, 2024

Sep 21, 2024

Xinhua News | Portuguese scientists discover new approach to combat Alzheimer's disease - Xinhua

Sep 21, 2024

Sep 16, 2024

After the Lykos debacle, what’s next for psychedelic therapies? - Pharmaceutical Technology

Sep 16, 2024

Sep 16, 2024

Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 - BioSpace

Sep 16, 2024

Sep 05, 2024

LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary - Yahoo Finance UK

Sep 05, 2024

Sep 04, 2024

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance UK

Sep 04, 2024

Sep 04, 2024

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - Yahoo Finance UK

Sep 04, 2024

Sep 03, 2024

LVTXLAVA Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Sep 03, 2024

Aug 22, 2024

LAVA Therapeutics (NASDAQ:LVTX) Given Market Outperform Rating at JMP Securities - Defense World

Aug 22, 2024

Aug 20, 2024

LAVA Reports Second Quarter 2024 Financial Results and Business Update - GlobeNewswire

Aug 20, 2024

Jun 10, 2024

LAVA Announces Annual Meeting of Shareholders - GlobeNewswire

Jun 10, 2024

Jun 02, 2024

Revenues Working Against LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Share Price Following 25% Dive - Simply Wall St

Jun 02, 2024

Mar 21, 2024

LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint - Yahoo Finance

Mar 21, 2024